Clinical Trial Detail

NCT ID NCT02025192
Title A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Seattle Genetics, Inc.
Indications

Her2-receptor positive breast cancer

Therapies

Capecitabine + Trastuzumab + Tucatinib

Trastuzumab + Tucatinib

Capecitabine + Tucatinib

Age Groups: adult senior

Additional content available in CKB BOOST